A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation

Hideki Nakasone, Junya Kanda, Shingo Yano, Yoshiko Atsuta, Hiroatsu Ago, Takahiro Fukuda, Kazuhiko Kakihana, Tatsuya Adachi, Toshiaki Yujiri, Shuichi Taniguchi, Jun Taguchi, Yasuo Morishima, Tokiko Nagamura, Hisashi Sakamaki, Takehiko Mori, Makoto Murata

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bronchiolitis obliterans syndrome (BOS) is a significant complication after allogeneic hematopoietic stem cell transplantation (HSCT). However, the pathogenesis and risks for the development of BOS have remained unclear. Therefore, a case-control study was conducted to investigate the risk factors for the development of BOS, which included the largest number of BOS cases; 196 patients with BOS were identified and compared with 1960 control recipients. The following were identified as significantly higher risk factors for the development of BOS: female recipients (OR 1.47, P = 0.019), ABO-mismatch HSCT (minor mismatch, OR 1.67, P = 0.015; major mismatch, OR 1.73, P = 0.012; bidirectional mismatch, OR 1.96, P = 0.018), busulfan+cyclophosphamide-based myeloablative conditioning (OR 1.74, P = 0.016), and acute graft-versus-host disease (GVHD) involving the skin (OR 1.55, P = 0.011). On the other hand, the risk for the development of BOS was significantly lower in patients receiving cord blood transplantation (OR 0.26, P = 0.0011). With respect to other target organs of chronic GVHD, ocular involvement was significantly associated with BOS (OR 2.53, P < 0.001). Prospective studies are required to elucidate the risk factors for the development of BOS, and future investigations should focus on finding a prophylactic approach against BOS based on these findings.

Original languageEnglish
Pages (from-to)631-639
Number of pages9
JournalTransplant International
Volume26
Issue number6
DOIs
Publication statusPublished - 2013 Jun

Fingerprint

Bronchiolitis Obliterans
Hematopoietic Stem Cell Transplantation
Case-Control Studies
Graft vs Host Disease
Busulfan
Fetal Blood
Cyclophosphamide
Transplantation
Prospective Studies

Keywords

  • ABO-mismatch
  • allogeneic hematopoietic stem cell transplantation
  • bronchiolitis obliterans syndrome
  • cord blood
  • graft-versus-host disease

ASJC Scopus subject areas

  • Transplantation

Cite this

A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. / Nakasone, Hideki; Kanda, Junya; Yano, Shingo; Atsuta, Yoshiko; Ago, Hiroatsu; Fukuda, Takahiro; Kakihana, Kazuhiko; Adachi, Tatsuya; Yujiri, Toshiaki; Taniguchi, Shuichi; Taguchi, Jun; Morishima, Yasuo; Nagamura, Tokiko; Sakamaki, Hisashi; Mori, Takehiko; Murata, Makoto.

In: Transplant International, Vol. 26, No. 6, 06.2013, p. 631-639.

Research output: Contribution to journalArticle

Nakasone, H, Kanda, J, Yano, S, Atsuta, Y, Ago, H, Fukuda, T, Kakihana, K, Adachi, T, Yujiri, T, Taniguchi, S, Taguchi, J, Morishima, Y, Nagamura, T, Sakamaki, H, Mori, T & Murata, M 2013, 'A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation', Transplant International, vol. 26, no. 6, pp. 631-639. https://doi.org/10.1111/tri.12093
Nakasone, Hideki ; Kanda, Junya ; Yano, Shingo ; Atsuta, Yoshiko ; Ago, Hiroatsu ; Fukuda, Takahiro ; Kakihana, Kazuhiko ; Adachi, Tatsuya ; Yujiri, Toshiaki ; Taniguchi, Shuichi ; Taguchi, Jun ; Morishima, Yasuo ; Nagamura, Tokiko ; Sakamaki, Hisashi ; Mori, Takehiko ; Murata, Makoto. / A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. In: Transplant International. 2013 ; Vol. 26, No. 6. pp. 631-639.
@article{799cf1a57f444000a56ae604a1d807f9,
title = "A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation",
abstract = "Bronchiolitis obliterans syndrome (BOS) is a significant complication after allogeneic hematopoietic stem cell transplantation (HSCT). However, the pathogenesis and risks for the development of BOS have remained unclear. Therefore, a case-control study was conducted to investigate the risk factors for the development of BOS, which included the largest number of BOS cases; 196 patients with BOS were identified and compared with 1960 control recipients. The following were identified as significantly higher risk factors for the development of BOS: female recipients (OR 1.47, P = 0.019), ABO-mismatch HSCT (minor mismatch, OR 1.67, P = 0.015; major mismatch, OR 1.73, P = 0.012; bidirectional mismatch, OR 1.96, P = 0.018), busulfan+cyclophosphamide-based myeloablative conditioning (OR 1.74, P = 0.016), and acute graft-versus-host disease (GVHD) involving the skin (OR 1.55, P = 0.011). On the other hand, the risk for the development of BOS was significantly lower in patients receiving cord blood transplantation (OR 0.26, P = 0.0011). With respect to other target organs of chronic GVHD, ocular involvement was significantly associated with BOS (OR 2.53, P < 0.001). Prospective studies are required to elucidate the risk factors for the development of BOS, and future investigations should focus on finding a prophylactic approach against BOS based on these findings.",
keywords = "ABO-mismatch, allogeneic hematopoietic stem cell transplantation, bronchiolitis obliterans syndrome, cord blood, graft-versus-host disease",
author = "Hideki Nakasone and Junya Kanda and Shingo Yano and Yoshiko Atsuta and Hiroatsu Ago and Takahiro Fukuda and Kazuhiko Kakihana and Tatsuya Adachi and Toshiaki Yujiri and Shuichi Taniguchi and Jun Taguchi and Yasuo Morishima and Tokiko Nagamura and Hisashi Sakamaki and Takehiko Mori and Makoto Murata",
year = "2013",
month = "6",
doi = "10.1111/tri.12093",
language = "English",
volume = "26",
pages = "631--639",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation

AU - Nakasone, Hideki

AU - Kanda, Junya

AU - Yano, Shingo

AU - Atsuta, Yoshiko

AU - Ago, Hiroatsu

AU - Fukuda, Takahiro

AU - Kakihana, Kazuhiko

AU - Adachi, Tatsuya

AU - Yujiri, Toshiaki

AU - Taniguchi, Shuichi

AU - Taguchi, Jun

AU - Morishima, Yasuo

AU - Nagamura, Tokiko

AU - Sakamaki, Hisashi

AU - Mori, Takehiko

AU - Murata, Makoto

PY - 2013/6

Y1 - 2013/6

N2 - Bronchiolitis obliterans syndrome (BOS) is a significant complication after allogeneic hematopoietic stem cell transplantation (HSCT). However, the pathogenesis and risks for the development of BOS have remained unclear. Therefore, a case-control study was conducted to investigate the risk factors for the development of BOS, which included the largest number of BOS cases; 196 patients with BOS were identified and compared with 1960 control recipients. The following were identified as significantly higher risk factors for the development of BOS: female recipients (OR 1.47, P = 0.019), ABO-mismatch HSCT (minor mismatch, OR 1.67, P = 0.015; major mismatch, OR 1.73, P = 0.012; bidirectional mismatch, OR 1.96, P = 0.018), busulfan+cyclophosphamide-based myeloablative conditioning (OR 1.74, P = 0.016), and acute graft-versus-host disease (GVHD) involving the skin (OR 1.55, P = 0.011). On the other hand, the risk for the development of BOS was significantly lower in patients receiving cord blood transplantation (OR 0.26, P = 0.0011). With respect to other target organs of chronic GVHD, ocular involvement was significantly associated with BOS (OR 2.53, P < 0.001). Prospective studies are required to elucidate the risk factors for the development of BOS, and future investigations should focus on finding a prophylactic approach against BOS based on these findings.

AB - Bronchiolitis obliterans syndrome (BOS) is a significant complication after allogeneic hematopoietic stem cell transplantation (HSCT). However, the pathogenesis and risks for the development of BOS have remained unclear. Therefore, a case-control study was conducted to investigate the risk factors for the development of BOS, which included the largest number of BOS cases; 196 patients with BOS were identified and compared with 1960 control recipients. The following were identified as significantly higher risk factors for the development of BOS: female recipients (OR 1.47, P = 0.019), ABO-mismatch HSCT (minor mismatch, OR 1.67, P = 0.015; major mismatch, OR 1.73, P = 0.012; bidirectional mismatch, OR 1.96, P = 0.018), busulfan+cyclophosphamide-based myeloablative conditioning (OR 1.74, P = 0.016), and acute graft-versus-host disease (GVHD) involving the skin (OR 1.55, P = 0.011). On the other hand, the risk for the development of BOS was significantly lower in patients receiving cord blood transplantation (OR 0.26, P = 0.0011). With respect to other target organs of chronic GVHD, ocular involvement was significantly associated with BOS (OR 2.53, P < 0.001). Prospective studies are required to elucidate the risk factors for the development of BOS, and future investigations should focus on finding a prophylactic approach against BOS based on these findings.

KW - ABO-mismatch

KW - allogeneic hematopoietic stem cell transplantation

KW - bronchiolitis obliterans syndrome

KW - cord blood

KW - graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=84877960821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877960821&partnerID=8YFLogxK

U2 - 10.1111/tri.12093

DO - 10.1111/tri.12093

M3 - Article

C2 - 23551210

AN - SCOPUS:84877960821

VL - 26

SP - 631

EP - 639

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 6

ER -